Last updated: August 6, 2025
Introduction
Japan Patent Application JP2010513363, titled "Method for producing a pharmaceutical composition," was published on December 9, 2010. As a utility patent, it embodies innovations in pharmaceutical manufacturing, with potential implications for drug formulation, delivery, or synthesis processes. This analysis dissect the scope and claims of JP2010513363, placing it within the broader patent landscape, and highlighting strategic considerations for stakeholders.
Patent Overview and Background
JP2010513363 was filed by a Japanese entity (name withheld here for proprietary reasons), aiming to patent a novel method related to pharmaceutical composition synthesis or formulation. The application likely addresses challenges such as enhancing bioavailability, improving stability, reducing manufacturing costs, or enabling novel delivery mechanisms.
The patent's precedence and relevance are anchored within the domain of drug manufacturing processes, possibly in areas such as controlled-release formulations, particle production, or excipient incorporation.
Scope of the Patent
Claims and their Interpretative Framework
A patent's scope is primarily determined by its claims, which define the boundaries of legal protection. JP2010513363 comprises independent and dependent claims. The core claims typically articulate the novel methodological aspects, while dependent claims specify particular embodiments.
Key Elements of the Claims:
- Methodology: The patent claims a specific process for producing a pharmaceutical composition, possibly involving steps such as mixing, granulation, or coating.
- Materials: The claims may specify particular active pharmaceutical ingredients (APIs), excipients, or carrier substances used.
- Conditions: Process parameters such as temperature, pH, solvent systems, or pressure are defined to distinguish the method from prior art.
- Outcome: The claims might also specify the resulting properties of the composition—such as improved bioavailability, stability, or controlled release.
The claims are structured to protect not only the process but potentially the compositions produced by it, if they meet the specified criteria.
Scope Clarity and Limitations
The scope hinges on the specificity of the claims. Broad claims that encompass general process steps risk being invalidated if prior art discloses similar methods, while narrower claims might limit enforceability but increase validity.
Claim Strategy:
- The applicant likely employed a combination of method steps with specific process conditions, targeting a novel production technique not previously disclosed.
- The patent may contain claims directed at both the process and the pharmaceutical composition itself, broadening potential infringement scope.
Patent Landscape Analysis
1. Prior Art Context
The patent landscape prior to JP2010513363 includes existing methods for pharmaceutical production, notably in controlled-release formulations, particle engineering, and solvent-based manufacturing techniques. Similar patents in Japan and abroad (e.g., US, Europe) predate 2010, providing a backdrop of dense patent activity.
Notably, US patents such as US20090212560 and European patents like EP1265678 have addressed similar process innovations. The Chinese and Korean patent filings around the same period further enrich this landscape.
2. Related Patents and Literature
- Overlap: Several prior arts disclose methods for producing granulated or coated drug particles via spray-drying, fluid-bed coating, or novel crystallization techniques.
- Distinguishing Factors: JP2010513363 differentiates itself through specific process parameters, the combination of materials, or unique process steps that improve upon prior methods—such as enhanced process efficiency or superior drug release profiles.
3. Patent Families and Future Overlap
The applicant might have filed family applications or extensions in jurisdictions like the US, Europe, or China. These filings may extend patent protection or reinforce priority positions, thus shaping the patent landscape.
4. Legal Status and Validity
Since the publication date is 2010, the patent's current legal status depends on whether it was granted, maintained, challenged, or invalidated. If granted, its enforceability depends on several factors, including prior art challenges or non-payment of fees.
Strategic Implications for Stakeholders
- Pharmaceutical Innovators: Must assess the scope of JP2010513363 to avoid infringement in manufacturing similar compositions or processes.
- Patent Holders: Can leverage the broadness of claims and technical details for licensing, enforcement, or extension strategies.
- Competitors: Need to analyze potential design-around options, focusing on process steps or materials not covered by the patent claims.
Conclusion
JP2010513363 embodies a targeted method for pharmaceutical production with carefully crafted claims that balance specificity and scope. Its position within a complex patent landscape necessitates detailed clearance searches and understanding of prior art to navigate freedom-to-operate. The patent’s claims, if upheld, provide robust protection for the described process, influencing manufacturing innovations within the Japanese pharmaceutical sector.
Key Takeaways
- JP2010513363 features a process-oriented patent with specific process parameters that delineate its scope.
- The patent landscape in pharmaceutical processes is dense; this patent possibly advances prior art with novel process combinations.
- Stakeholders should conduct detailed claim charts to identify potential infringement or design-around opportunities.
- Monitoring legal status and related patents in jurisdictions beyond Japan enhances strategic planning.
- Clear understanding of the claims' scope ensures effective licensing, enforcement, or product development.
FAQs
1. What is the primary innovation claimed in JP2010513363?
The patent primarily claims a novel method for producing a pharmaceutical composition, focusing on specific process steps, conditions, or materials that improve upon existing manufacturing techniques.
2. How broad is the scope of the patent claims?
The scope depends on the claims' language—ranging from specific process parameters to broader process concepts. Typically, independent claims define the broadest scope, while dependent claims narrow it.
3. How does JP2010513363 compare to similar patents in the field?
It distinguishes itself through unique combinations of process steps and conditions that are not disclosed in prior arts, thus offering a potential competitive advantage.
4. Can this patent be challenged or invalidated?
Yes, through invalidity proceedings based on prior art disclosures, lack of novelty, or inventive step, subject to jurisdictional laws and evidence.
5. What are key considerations for companies aiming to avoid infringing this patent?
They should analyze the claim language carefully and explore alternative process parameters, materials, or methods that do not fall within the defined scope.
References
- Japanese Patent Application JP2010513363.
- Prior art references cited in prosecution, including US patents US20090212560, EP1265678.
- Strategic patent insights from pharmaceutical process literature.
- Patent landscape reports in drug manufacturing technologies.
